A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma (Brain Tumors)
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Sponsor: Karyopharm Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT0359
U.S. Govt. ID: NCT04421378
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop growing. Selinexor is approved by the U.S. Food and Drug Administration (FDA) for the use in certain patients with multiple myeloma but has not yet been approved by the FDA for the treatment of your type of cancer.
Investigator
Andrew Lassman, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a confirmed diagnosis of glioblastoma? Yes No
Are you willing to provide tumor tissue and blood samples for future genetic testing? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162